114 related articles for article (PubMed ID: 34242968)
1. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
[TBL] [Abstract][Full Text] [Related]
2. Molecular Screening in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: Anaplastic Lymphoma Kinase Analysis, Next-Generation Sequencing Fusion Gene Detection, and T-Cell Receptor Immunoprofiling.
Kalinova M; Mrhalova M; Kabickova E; Svaton M; Skotnicova A; Prouzova Z; Krenova Z; Kolenova A; Divoka M; Fronkova E; Kodet R
Mod Pathol; 2024 Mar; 37(3):100428. PubMed ID: 38266918
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma.
Xu W; Kim JW; Jung WJ; Koh Y; Yoon SS
Cancer Res Treat; 2018 Apr; 50(2):599-613. PubMed ID: 28675026
[TBL] [Abstract][Full Text] [Related]
5. Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis.
Mduff FK; Hook CE; Tooze RM; Huntly BJ; Pandolfi PP; Turner SD
Lab Invest; 2011 Sep; 91(9):1298-303. PubMed ID: 21709672
[TBL] [Abstract][Full Text] [Related]
6. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
[TBL] [Abstract][Full Text] [Related]
7. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
Song Z; Wu W; Wei W; Xiao W; Lei M; Cai KQ; Huang DW; Jeong S; Zhang JP; Wang H; Kadin ME; Waldmann TA; Staudt LM; Nakagawa M; Yang Y
Blood; 2023 Oct; 142(15):1297-1311. PubMed ID: 37339580
[TBL] [Abstract][Full Text] [Related]
8. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Mastini C; Campisi M; Patrucco E; Mura G; Ferreira A; Costa C; Ambrogio C; Germena G; Martinengo C; Peola S; Mota I; Vissio E; Molinaro L; Arigoni M; Olivero M; Calogero R; Prokoph N; Tabbò F; Shoji B; Brugieres L; Geoerger B; Turner SD; Cuesta-Mateos C; D'Aliberti D; Mologni L; Piazza R; Gambacorti-Passerini C; Inghirami GG; Chiono V; Kamm RD; Hirsch E; Koch R; Weinstock DM; Aster JC; Voena C; Chiarle R
Sci Transl Med; 2023 Jun; 15(702):eabo3826. PubMed ID: 37379367
[TBL] [Abstract][Full Text] [Related]
9. Detection of TRAF1-ALK fusion in skin lesions of systemic ALK+ anaplastic large cell lymphoma initially involving the skin and the draining lymph node.
Norimatsu Y; Akatsuka T; Matsuoka A; Hamada T; Mori I; Shiomi T; Mori N; Onishi K; Togashi Y; Inoue N; Takeuchi K; Sugaya M
J Dermatol; 2024 Jan; 51(1):120-124. PubMed ID: 37753577
[TBL] [Abstract][Full Text] [Related]
10. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma.
Mu W; Zhang M; Hu G; Han Y; Mao X; Chen C; Shen K; Dai Z; Zhu X; Zhou X; Huang L; Ao Q; Xiao M
Front Immunol; 2023; 14():1280007. PubMed ID: 38143760
[TBL] [Abstract][Full Text] [Related]
11. Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function.
Zhang Q; Basappa J; Wang HY; Nunez-Cruz S; Lobello C; Wang S; Liu X; Chekol S; Guo L; Ziober A; Nejati R; Shestov A; Feldman M; Glickson JD; Turner SD; Blair IA; Van Dang C; Wasik MA
Leukemia; 2023 Dec; 37(12):2436-2447. PubMed ID: 37773266
[TBL] [Abstract][Full Text] [Related]
12. The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
Dang Q; Chen L; Xu M; You X; Zhou H; Zhang Y; Shi W
Cell Signal; 2019 Jul; 59():76-84. PubMed ID: 30878517
[TBL] [Abstract][Full Text] [Related]
13. Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
Luedersen J; Stadt UZ; Richter J; Oschlies I; Klapper W; Rosenwald A; Kalinova M; Simonitsch-Klupp I; Siebert R; Zimmermann M; Qi M; Nakel J; Scheinemann K; Knörr F; Attarbaschi A; Kabickova E; Woessmann W; Damm-Welk C
Br J Haematol; 2024 Jan; ():. PubMed ID: 38279625
[TBL] [Abstract][Full Text] [Related]
14. ALK-negative CNS anaplastic large cell lymphoma: case report and review of literature.
Lannon M; Lu JQ; Chum M; Wang BH
Br J Neurosurg; 2023 Oct; 37(5):1245-1250. PubMed ID: 33253051
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA mitophagy and ALK-negative anaplastic lymphoma-associated transcript: a novel regulator of mitophagy in T-cell lymphoma.
Mularoni V; Donati B; Tameni A; Manicardi V; Reggiani F; Sauta E; Zanelli M; Tigano M; Vitale E; Torricelli F; Ascani S; Martino G; Inghirami G; Sanguedolce F; Ruffini A; Bavieri A; Luminari S; Pizzi M; Dei Tos AP; Fesce C; Neri A; Ciarrocchi A; Fragliasso V
Haematologica; 2023 Dec; 108(12):3333-3346. PubMed ID: 37381763
[TBL] [Abstract][Full Text] [Related]
16. A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.
Kawasoe K; Watanabe T; Yoshida-Sakai N; Yamamoto Y; Kurahashi Y; Kidoguchi K; Ureshino H; Kamachi K; Fukuda-Kurahashi Y; Kimura S
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894456
[TBL] [Abstract][Full Text] [Related]
17. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.
Noguchi K; Ikawa Y
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278
[TBL] [Abstract][Full Text] [Related]
18. Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors.
Lowe E; Mossé YP
Oncol Ther; 2024 Apr; ():. PubMed ID: 38676786
[TBL] [Abstract][Full Text] [Related]
19. STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma.
Prutsch N; He S; Berezovskaya A; Durbin AD; Dharia NV; Maher KA; Matthews JD; Hare L; Turner SD; Stegmaier K; Kenner L; Merkel O; Look AT; Abraham BJ; Zimmerman MW
Cell Rep Med; 2024 Mar; 5(3):101472. PubMed ID: 38508140
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
